<DOC>
	<DOCNO>NCT00002778</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Combining chemotherapy allogeneic bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood , may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness allogeneic bone marrow transplantation follow sargramostim treating patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Sargramostim Following Allogeneic Bone Marrow Transplantation Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether use sargramostim ( GM-CSF ) T-cell deplete , CD34-positive cell-supplemented allogeneic bone marrow transplantation reduce leukemic relapse patient chronic myelogenous leukemia . OUTLINE : Patients receive myeloablation busulfan cyclophosphamide approve protocol . Allogeneic bone marrow harvest treated vitro anti-CD34 antibody . T-cell deplete , CD34-positive cell-supplemented bone marrow infuse day 0 . Patients receive high-dose sargramostim ( GM-CSF ) subcutaneously ( SC ) begin day 5 continue blood count recover low-dose GM-CSF SC continue day 60 . Donor lymphocyte infusion second unmodified allogeneic bone marrow transplantation without GM-CSF consider case primary secondary engraftment failure . Patients follow every month 3 month , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study within approximately 6-10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia ( CML ) document cytogenetic molecular analysis Johns Hopkins Philadelphia chromosome ( Ph ) positive negative CML Phnegative CML allow presence either : BCRABL rearrangement ( molecular , fluorescent situ hybridization , polymerase chain reaction analysis ) p210 protein One following : Patient age 18 65 Disease duration longer 3 year Accelerated phase CML Accelerated phase diagnosis base follow : More 10 % le 30 % blast blood bone marrow No hematologic response prior conventional therapy ( hydroxyurea interferon ) Extramedullary disease ( e.g. , progressive splenomegaly lymphadenopathy ) Basophilia great 10 % blood bone marrow Other cytogenetic abnormality addition single Ph chromosome Second chronic phase Failure interferon suggest patient age 18 chronic phase CML , failure define : No detectable Phnegative metaphase marrow 6 month No progressive increase Phnegative metaphases marrow 612 month Less 50 % Phnegative metaphase 1 year No complete cytogenetic remission 2 year Intolerance interferon therapy No blast crisis CML , chronic myelomonocytic leukemia , juvenile CML The following condition allow : Leukocyte count abnormality Fibrosis Anemia Fever bone pain Thrombocytopenia Bone marrow reticulin Availability HLAidentical sibling donor At least 3 year age ( priority give donor age 10 ) Priority give CMVnegative donor patient CMVnegative No medical psychiatric condition precludes transplant procedure PATIENT CHARACTERISTICS : Age 18 65 Performance status ECOG 01 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Not specify Renal Not specify Other No history intolerance sargramostim ( GMCSF ) PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
</DOC>